Citations

Showing 10 of 108162 citations.

Pulmonary Pseudoneoplasms
Yi, Eunhee S. , Aubry, Marie‐Christine, Aubry, Marie-Christine

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 134 | Issue: 3 | Pages: 417-426

10.5858/134.3.417 | PMID 20196669 Get It

Abstract Context. —Not uncommonly, a surgical pathologist will be requested to review excised material, with a clinical diagnosis of cancer, in which no malignancy can be identified. Often, sampling may be the issue. However, different nonneoplastic processes may mimic cancer clinically and not be recognized histologically. These are commonly referred to as pseudoneoplasms and can involve the lung, pleura, and mediastinum. Objective. —To review the most commonly encountered pseudoneoplasms of the thoracic cavity in surgical pathology and discuss the main differential diagnosis. Data Sources. —Literature and personal review of cases with focus on inflammatory pseudotumors of the lung, organizing pneumonia, nodular lymphoid hyperplasia, apical cap, round atelectasis, and sclerosing mediastinitis with its pulmonary counterpart, hyalinizing granuloma. Conclusions. —When reviewing specimens that appear nondiagnostic for malignancy, it is important to consider one of these pseudoneoplasms in the differential diagnosis as they may explain the clinical and radiologic information.
Pseudoneoplasms of the Nervous System
Donev, Kliment , Scheithauer, Bernd W.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 134 | Issue: 3 | Pages: 404-416

10.5858/134.3.404 | PMID 20196668 Get It

Abstract Context. —Pseudoneoplasms of the nervous system vary greatly in nature. Ranging from inflammatory to autoimmune, infectious, malformative, reactive, degenerative, and radiation induced, they all mimic true tumors. Thus, they have the potential to mislead clinicians, radiologists, and pathologists alike. Their clinical and/or neuroimaging and histologic features are readily misinterpreted as tumor. Knowledge of the pitfalls is essential to avoid mismanagement, specifically overtreatment. In such instances, pathologists must take the entire clinical picture into consideration, acquainting themselves with presenting symptoms, physical findings, and neuroimaging. Objective. —To present 10 examples of pseudoneoplasms of the nervous system, analyze the basis for their mimicry, and discuss their differential diagnosis. Data Sources. —Review of the pertinent literature related to pseudoneoplasms of the nervous system and review of the consultation files of one of the authors (B.W.S.). Conclusions. —The identification of tumor mimics may be difficult under the best of circumstances, and maintaining a broad differential diagnosis as well as application of a variety of immunocytochemical and occasionally ultrastructural and/or molecular genetic methods is essential to arrive at a correct diagnosis.
Pseudoneoplasms of the Gastrointestinal Tract
Leung, Stanley T., De Petris, Giovanni, Petris, Giovanni De

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 134 | Issue: 3 | Pages: 378-392

10.5858/134.3.378 | PMID 20196666 Get It

Abstract Context. —The pathologist plays the leading role in distinguishing pseudoneoplasms from truly neoplastic lesions in the gastrointestinal tract. Objective. —This review was conducted to heighten awareness of pseudoneoplasms, to help differentiate among the various types of pseudoneoplasms, and to help distinguish pseudoneoplasms from malignancies. Data Sources. —This review is based on the medical literature on pseudoneoplasms in MEDLINE and the authors' own experiences. Reference lists of retrieved articles were also reviewed to identify additional articles. Conclusions. —A classification of pseudoneoplasms, according to the mechanism of injury to the gastrointestinal tract, morphologic patterns, and heterotopia, may be useful in providing a diagnostic framework in which ancillary techniques often have a diagnostic role. Several pseudoneoplasms may be closely associated with true neoplasms (eg, malakoplakia, prolapsetype lesions) because of the nonspecific nature of the response of the intestine to injury.
Cardiovascular Pseudoneoplasms
Miller, Dylan V. , Tazelaar, Henry D. , Tazelaar, Henry D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 134 | Issue: 3 | Pages: 362-368

10.5858/134.3.362 | PMID 20196664 Get It

Abstract Context. —Primary cardiac tumors are rare and the great majority are benign neoplasms. Mass-forming reactive and pseudoneoplastic growths are less common, but recognizing and distinguishing these lesions from the neoplasms they resemble is critical to appropriate patient care. Objective. —The general clinical, imaging, gross pathologic, and histologic features of 5 important pseudoneoplasms (inflammatory myofibroblastic tumor, hamartoma of mature cardiac myocytes, mesothelial/monocytic cardiac excrescences, calcified amorphous tumor, and lipomatous hypertrophy of the atrial septum) are discussed, with an emphasis on features differentiating them from other benign and malignant tumors. Data Sources. —Pertinent citations of the literature and observations from the authors' experience are drawn upon. Conclusions. —While lacking malignant potential, these lesions can be associated with considerable morbidity and occasional mortality. Their recognition is important in guiding patient management, providing both guidance for appropriate therapy and avoidance of inappropriately aggressive and toxic treatments.
Significant and Unexpected, and Critical Diagnoses in Surgical Pathology: A College of American Pathologists' Survey of 1130 Laboratories
Nakhleh, Raouf E. , Souers, Rhona J., Brown, Richard W.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 133 | Issue: 9 | Pages: 1375-1378

10.5858/133.9.1375 | PMID 19722742 Get It

Abstract Context. —The Joint Commission and the College of American Pathologists have emphasized improved communication as a strategy to improve patient safety and reduce errors. Objective. —To determine current policies and practices concerning critical and/or significant and unexpected results in anatomic pathology. Design. —A survey was distributed with the 2007 D mailing of the Performance Improvement Program slides. The survey included questions that determined laboratory size, practice setting, and anatomic pathology critical and/or significant and unexpected result policies and practices. Results. —Surveys from 1130 laboratories were received. A total of 75% had a written policy regarding anatomic pathology critical and/or significant and unexpected results; 25% did not. A total of 30% of laboratories with written policies stated that their policies included guidelines but did not include specific examples. A total of 33% listed 5 or fewer specific examples, 18% listed more than 5 examples, and 19% stated that they had a specifically defined list of significant and unexpected and/or critical diagnoses. The conditions that were listed included malignancies (48% of all laboratories), findings not expected by the clinical history (45%), life-threatening infections (45%), no chorionic villi in products of conception (37%), inflammatory or immunologic processes (19%), and organ rejection (14%). Laboratories with a higher median number of accessioned surgical and cytology cases and independent laboratories tended to have policies with more than 5 specific examples or precise lists of must-call diagnoses ( P < .001). Conclusions. —This survey illustrates current anatomic pathology policies and practices with respect to critical and significant and unexpected results.
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group
Husain, Aliya N. , Colby, Thomas V. , Ordóǹez, Nelson G., Krausz, Thomas, Borczuk, Alain , Cagle, Philip T., Gibbs, A R, Gown, Allen M. , Hammar, Samuel P. , Litzky, Leslie A., Roggli, Victor L., Chirieac, Lucian R. , Churg, Andrew , Galateau-Sallé, Françoise , Travis, William D. , Wick, Mark R.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 133 | Issue: 8 | Pages: 1317-1331

10.5858/133.8.1317 | PMID 19653732 Get It

Abstract Context. —Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. Objective. —To develop practical guidelines for the pathologic diagnosis of MM. Data Sources. —A pathology panel was convened at the International Mesothelioma Interest Group biennial meeting (October 2006). Pathologists with an interest in the field also contributed after the meeting. Conclusions. —There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. The International Mesothelioma Interest Group recommends that markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.
LKB1/ STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms
Marinaccio, Christian , Suraneni, Praveen, Celik, Hamza , Volk, Andrew , Wen, Qiang , Ling, Te , Bulic, Marinka , Famulare, Christopher , Farnoud, Noushin , Stein, Brady L. , Schieber, Michael , Younger, Scott T. , Gangat, Naseema , Ntziachristos, Panagiotis , Chandel, Navdeep S. , Levine, Ross L. , Rampal, Raajit K. , Challen, Grant A. , Tefferi, Ayalew , Crispino, John D. , Schieber, Michael , Root, David E , Rampal, Raajit K , Crispino, John D , Wen, Qiang Jeremy, Lasho, Terra L. , Koche, Richard P , Gurbuxani, Sandeep K. , Hoffman, Ronald

Mayo Clinic

Cancer Discovery | February 12, 2021 | Volume: 11 | Issue: 6 | Pages: 1398-1410

10.1158/2159-8290.cd-20-1353 | PMID 33579786 Get It

Abstract The myeloproliferative neoplasms (MPN) frequently progress to blast phase disease, an aggressive form of acute myeloid leukemia. To identify genes that suppress disease progression, we performed a focused CRISPR/Cas9 screen and discovered that depletion of LKB1/Stk11 led to enhanced in vitro self-renewal of murine MPN cells. Deletion of Stk11 in a mouse MPN model caused rapid lethality with enhanced fibrosis, osteosclerosis, and an accumulation of immature cells in the bone marrow, as well as enhanced engraftment of primary human MPN cells in vivo. LKB1 loss was associated with increased mitochondrial reactive oxygen species and stabilization of HIF1α, and downregulation of LKB1 and increased levels of HIF1α were observed in human blast phase MPN specimens. Of note, we observed strong concordance of pathways that were enriched in murine MPN cells with LKB1 loss with those enriched in blast phase MPN patient specimens, supporting the conclusion that STK11 is a tumor suppressor in the MPNs. Significance: Progression of the myeloproliferative neoplasms to acute myeloid leukemia occurs in a substantial number of cases, but the genetic basis has been unclear. We discovered that loss of LKB1/STK11 leads to stabilization of HIF1a and promotes disease progression. This observation provides a potential therapeutic avenue for targeting progression. This article is highlighted in the In This Issue feature, p. 1307
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
Vance, Gail H. , Barry, Todd, Bloom, Kenneth J., Hicks, David G., Jenkins, Robert B. , Persons, Diane L., Tubbs, Raymond R., Hammond, M. Elizabeth H. , Fitzgibbons, Patrick L.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 133 | Issue: 4 | Pages: 611-612

10.5858/133.4.611 | PMID 19391661 Get It

Abstract Context. —Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5% to 30%. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. Objectives. —To define HER2 genetic heterogeneity and to provide practice guidelines for examining and reporting breast tumors with genetic heterogeneity for improvement of HER2 testing in breast cancer. Design. —We convened an expert panel to discuss HER2 gene amplification testing by fluorescence in situ hybridization. Components addressed included a definition of HER2 amplification heterogeneity, practice guidelines for examination of the tissue, and reporting criteria for this analysis. Results. —Genetic heterogeneity for amplification of HER2 gene status in invasive breast cancer is defined and guidelines established for assessing and reporting HER2 results in these cases. These guidelines are additive to and expand those published in 2007 by the American Society of Clinical Oncology and the College of American Pathologists. Conclusion. —Standardized methods for analysis will improve the accuracy and consistency of interpretation of HER2 gene amplification status in breast cancer.
Heart–lung transplant in congenitally corrected transposition of the great arteries and dextrocardia patient
Ahmed, Magdy M. El‐Sayed , Thomas, Mathew , Makey, Ian A. , Erasmus, D , Sareyyüpoğlu, Başar , Landolfo, Kevin , Thomas, Mathew , El-Sayed Ahmed, Magdy M , Martin, Archer K, Landolfo, Kevin P, Pham, Si M. , Thomas, Mathew , Martin, Archer Kilbourne

Mayo Clinic

SAGE Open Medical Case Reports | February 12, 2021 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/2050313x20987449 | PMID 33633862 Get It

A 53-year-old male patient was presented to our institution with the clinical picture of biventricular failure. The echocardiogram revealed congenitally corrected transposition of the great arteries, dextrocardia with situs solitus, atrioventricular discordance and ventriculoatrial discordance, severe systemic and mitral valves regurgitation, and severe pulmonary hypertension (mean pulmonary artery pressure: 51 mm Hg). He underwent heart–lung transplant. He was discharged on postoperative day 25 with left ventricular ejection fraction of 60%–65%, and with oxygen independency.
Unsatisfactory Reporting Rates: 2006 Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology
Moriarty, Ann , Clayton, Amy C., Zaleski, Sue, Henry, Michael , Schwartz, Mary R. , Eversole, Galen M., Tench, William D., Fatheree, Lisa A., Souers, Rhona J., Wilbur, David C.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 133 | Issue: 12 | Pages: 1912-1916

10.5858/133.12.1912 | PMID 19961244 Get It

Abstract Context.—Minimum cellular criteria for satisfactory Papanicolaou tests were established with the Bethesda System in 2001, and unsatisfactory rates are used as a quality-reporting measure. Objective.—To evaluate practices and unsatisfactory rates from laboratories responding to the 2007 College of American Pathologists supplemental questionnaire survey. Design.—In 2007, a supplemental questionnaire was mailed to 1621 laboratories enrolled in the 2006 College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology (PAP Education), requesting data from the 2006 calendar year. Unsatisfactory rates, reasons for unsatisfactory specimens, laboratory size, and specimen preparation type were analyzed. Results.—A total of 42% of the laboratories responded to the survey. Most of those laboratories (637 of 674; 94.5%) used the Bethesda System minimum cellularity criteria. Of those laboratories responding, 79% (527 of 667) used the Bethesda System criteria for atrophic or postirradiation specimens. Unsatisfactory rates have increased since 1996. SurePath preparations were associated with the lowest unsatisfactory rate (50th percentile, 0.30; 95th percentile, 1.3), conventional Papanicolaou tests had the highest 95th percentile rates (50th percentile, 1.0; 95th percentile, 5.90), and ThinPrep specimens had the highest median percentile (50th percentile, 1.1; 95th percentile, 3.4). The most-common reason for unsatisfactory Papanicolaou tests was too few squamous cells. Air-drying artifact was the least-common reason for unsatisfactory reporting for liquid-based preparations. Conclusions.—Use of the Bethesda System criteria for unsatisfactory specimens is widespread. Unsatisfactory rates have increased since 1996; however, the median rates are 1.1% or less for all preparations. Results from the College of American Pathologists PAP Education supplemental questionnaire continue to provide valuable benchmarking data for cytologic quality-improvement programs in laboratories.